Could I be wrong? Exploring cognitive bias, curiosity, intellectual humility, and lifelong learning

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing eight time­ly sci­en­tif­ic and indus­try news plus a few fun teasers to appre­ci­ate our unique human brains. #1. Could I be wrong? Explor­ing research on cog­ni­tive bias, curios­i­ty, intel­lec­tu­al humil­i­ty, and life­long learn­ing “None of us thinks that our beliefs and atti­tudes are incor­rect; if we…

Read More

Click Therapeutics raises further $52M to build up digital therapeutics pipeline for depression, insomnia, smoking cessation and more

With Sanofi still on board, Click Ther­a­peu­tics clos­es $52M series B for dig­i­tal ther­a­peu­tics in depres­sion, chron­ic pain and more (Fierce Biotech): Anoth­er medtech devel­op­er’s plans to cre­ate dig­i­tal ther­a­peu­tics to treat a wide range of ill­ness­es are click­ing into place, thanks to a third mul­ti­mil­lion-dol­lar invest­ment in Click Ther­a­peu­tics in bare­ly a year.

Read More

How to intervene early to address brain/ mental health problems: Examples in depression, epilepsy and smoking cessation

How to inter­vene ear­ly: Exam­ples in depres­sion, epilep­sy and smok­ing ces­sa­tion from Sharp­Brains We hope you enjoy this slid­edeck sup­port­ing a fas­ci­nat­ing, for­ward-look­ing ses­sion held at the 2019 Sharp­Brains Vir­tu­al Sum­mit: The Future of Brain Health (March 7–9th).  Full record­ings are avail­able for pur­chase here. 10.45am-12.15pm. How to inter­vene ear­ly: Exam­ples in depres­sion, epilep­sy and smok­ing ces­sa­tion  Dr. Wal­ter Greenleaf,…

Read More

Sanofi Ventures leads $17M investment in Click Therapeutics, finalist @ 2017 Brainnovations Pitch Contest

Sanofi Backs Click Ther­a­peu­tics as Dig­i­tal Med­i­cines Gain Momen­tum (Xcon­o­my): “Drug mak­ers are mak­ing more bets on the nascent field of dig­i­tal med­i­cine. The lat­est exam­ple: Click Ther­a­peu­tics announced Mon­day that it grabbed a $17 mil­lion invest­ment led by Sanofi Ven­tures, the Cam­bridge, MA-based ven­ture cap­i­tal arm of the French phar­ma­ceu­ti­cal giant.

Read More

Sneak preview into the future of mental health: Fully digital clinical trials to study digital therapeutics

——– Click Ther­a­peu­tics™ Reports Pre­lim­i­nary Results of a 416-Par­tic­i­­pant Clin­i­cal Study Demon­strat­ing Excep­tion­al Engage­ment and Effi­ca­cy of Click­o­tine®, a Patent-Pend­ing Dig­i­tal Ther­a­peu­tics™ Pro­gram for Smok­ing Ces­sa­tion (press release): “Click Ther­a­peu­tics, Inc. (“Click”), a com­pa­ny devel­op­ing a suite of per­son­al­ized data-dri­ven dig­i­tal ther­a­peu­tics for chron­ic health con­di­tions, announces today pre­lim­i­nary results of its ful­ly remote clinical…

Read More